These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33950341)

  • 1. Current experimental therapies for atypical and malignant meningiomas.
    Corona AM; Di L; Shah AH; Crespo R; Eichberg DG; Lu VM; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2021 Jun; 153(2):203-210. PubMed ID: 33950341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.
    Maggio I; Franceschi E; Tosoni A; Nunno VD; Gatto L; Lodi R; Brandes AA
    CNS Oncol; 2021 Jun; 10(2):CNS72. PubMed ID: 34015955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.
    Delgado-López PD; Corrales-García EM
    Clin Transl Oncol; 2021 Feb; 23(2):205-221. PubMed ID: 32651886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review.
    Wu A; Jin MC; Meola A; Wong HN; Chang SD
    Neurosurg Focus; 2019 Jun; 46(6):E12. PubMed ID: 31153145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.
    Brown DA; Goyal A; Kerezoudis P; Alvi MA; Himes BT; Bydon M; Van Gompel JJ; Chaichana KL; Quiñones-Hinojosa A; Burns TC; Yan E; Parney IF
    J Neurooncol; 2020 Sep; 149(2):293-303. PubMed ID: 32860156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis.
    Reddy AK; Ryoo JS; Denyer S; McGuire LS; Mehta AI
    Neurosurg Focus; 2019 Jun; 46(6):E3. PubMed ID: 31153148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
    Unterberger A; Nguyen T; Duong C; Kondajji A; Kulinich D; Yang I
    J Neurooncol; 2021 Apr; 152(2):205-216. PubMed ID: 33635510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Atypical and Anaplastic Meningiomas.
    Buttrick S; Shah AH; Komotar RJ; Ivan ME
    Neurosurg Clin N Am; 2016 Apr; 27(2):239-47. PubMed ID: 27012388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and Prognostic Predictors of Anaplastic Meningiomas.
    Masalha W; Heiland DH; Delev D; Fennell JT; Franco P; Scheiwe C; Mercas BI; Mader I; Schnell O; Grauvogel J
    World Neurosurg; 2019 Nov; 131():e321-e328. PubMed ID: 31356972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Related mechanisms, current treatments, and new perspectives in meningioma.
    Inetas-Yengin G; Bayrak OF
    Genes Chromosomes Cancer; 2024 May; 63(5):e23248. PubMed ID: 38801095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in meningioma therapy.
    Norden AD; Drappatz J; Wen PY
    Curr Neurol Neurosci Rep; 2009 May; 9(3):231-40. PubMed ID: 19348712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma.
    Hemmati SM; Ghadjar P; Grün A; Badakhshi H; Zschaeck S; Senger C; Acker G; Misch M; Budach V; Kaul D
    Radiat Oncol; 2019 Sep; 14(1):160. PubMed ID: 31477146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
    Sioka C; Kyritsis AP
    J Neurooncol; 2009 Mar; 92(1):1-6. PubMed ID: 19023520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of Pharmacotherapy in Treatment of Meningiomas].
    Tamura R
    No Shinkei Geka; 2024 Jul; 52(4):825-838. PubMed ID: 39034520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
    Modha A; Gutin PH
    Neurosurgery; 2005 Sep; 57(3):538-50; discussion 538-50. PubMed ID: 16145534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization Grade III Meningiomas: A Retrospective Study at an Academic Medical Center.
    Sá-Marta E; Alves JL; Rebelo O; Barbosa M
    World Neurosurg; 2021 May; 149():e877-e893. PubMed ID: 33516862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
    Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
    J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the systemic therapy for recurrent meningiomas and the challenges ahead.
    Li Y; Drappatz J
    Expert Rev Neurother; 2023; 23(11):995-1004. PubMed ID: 37695700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clear cell histology portends a worse prognosis than other WHO grade II histologies.
    Soni P; Shao J; Momin A; Lopez D; Angelov L; Mohammadi AM; Barnett GH; Recinos PF; Kshettry VR
    J Neurooncol; 2021 Jan; 151(2):307-312. PubMed ID: 33398533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.